Elisa Sala

Ulm, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Hospital-Based Models of Immunization for High-Risk Subjects in Lombardy (Italy): A Region-Wide Assessment of Implementation and Progress.

Hospital-Based Models of Immunization for High-Risk Subjects in Lombardy (Italy): A Region-Wide Assessment of Implementation and Progress.

Journal: Vaccines
Published: April 14, 2026

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Journal: British journal of haematology
Published: March 04, 2026

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Journal: Frontiers in immunology
Published: February 28, 2026

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Journal: Frontiers in immunology
Published: January 18, 2026

Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units.

Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units.

Journal: Current oncology (Toronto, Ont.)
Published: December 19, 2025

Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.

Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.

Journal: Haematologica
Published: November 10, 2025

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

Journal: Bone marrow transplantation
Published: September 05, 2025

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Journal: Bone marrow transplantation
Published: May 29, 2025

HIV and hospitals between knowledge and stigma.

HIV and hospitals between knowledge and stigma.

Journal: AIDS care
Published: January 30, 2025

Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST.

Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST.

Journal: Transplantation and cellular therapy
Published: December 06, 2024

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.

Journal: Leukemia research
Published: August 30, 2024

Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study.

Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study.

Journal: Bone marrow transplantation
Published: August 21, 2024
Showing 1-12 of 46

Last Updated: 09/26/2026